| Family Care Services Inc | |
| 2500 Minnehaha Avenue South, Minneapolis, Minnesota 55404 | |
| (612) 340-0733 | |
| Name | Family Care Services Inc |
|---|---|
| Location | 2500 Minnehaha Avenue South, Minneapolis, Minnesota |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 248077 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 55007, 55012, 55014, 55024, 55025, 55037, 55044, 55051, 55056, 55063, 55069, 55075, 55077, 55079, 55082, 55101, 55102, 55104, 55105, 55106, 55107, 55109, 55110, 55112, 55113, 55116, 55117, 55119, 55121, 55122, 55124, 55125, 55126, 55127, 55128, 55129, 55130, 55306, 55311, 55316, 55331, 55337, 55344, 55345, 55346, 55364, 55369, 55374, 55379, 55391, 55401, 55403, 55404, 55405, 55406, 55407, 55408, 55409, 55411, 55412, 55413, 55414, 55416, 55417, 55418, 55419, 55420, 55421, 55422, 55423, 55424, 55426, 55427, 55428, 55429, 55430, 55431, 55432, 55433, 55434, 55435, 55436, 55437, 55442, 55443, 55444, 55445, 55446, 55447, 55704, 55735, 56358 |
| NPI Number | 1184896896 |
| Organization Name | FAMILY HOME HEALTH CARE, INC. |
| Address | 2525 E Franklin Ave, 101, Minneapolis, MN 55406 |
| Phone Number | 612-340-0733 |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
| NPI Number | 1659313096 |
| Organization Name | FAMILY CARE SERVICES INC |
| Address | 2525 E Franklin Ave, Suite 101, Minneapolis, MN 55406 |
| Phone Number | 612-340-0733 |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
| Quality Rating: |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 89 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 96.6 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.2 | 99.6 |
| How often the home health team checked patients for depression | 97.9 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 72 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 89.9 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 96.3 | 96.4 |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 58 | 79.6 |
| How often patients got better at getting in and out of bed | 54.5 | 81.1 |
| How often patients got better at bathing | 65 | 82.3 |
| How often patients’ breathing improved | 53.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 100 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 54.7 | 75 |
| How often home health patients had to be admitted to the hospital | 29.1 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 10.1 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 92.4 | 94 |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
The patient survey data of Family Care Services Inc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 81 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 80 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 78 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 72 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 69 | 78 |
News Archive
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Fewer than 10% of people who experience sudden cardiac arrest (SCA) outside of a hospital survive. Reoccurrence rates after an initial event are high, which is why current Canadian Cardiovascular Society, as well as other international guidelines, strongly recommend the use of implantable cardioverter defibrillators (ICDs) in selected patients who survive cardiac arrest.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Insufficient sleep, a common problem that has been linked to chronic disease risk, might also be an unrecognized risk factor for bone loss. Results of a new study will be presented Saturday at the Endocrine Society's 99th annual meeting in Orlando, Fla.
There are small but statistically significant differences in rates of common mental disorders between people living in urban and rural areas, according to a new study published in the January 2006 issue of the British Journal of Psychiatry.
› Verified 5 days ago
Fairview Home Care And Hospice Location: 2450 26th Avenue South, Minneapolis, Minnesota 55406 Ratings: Phone: (612) 721-2491 | |
Childrens Home Care And Hospice Location: 2525 Chicago Avenue South, Minneapolis, Minnesota 55404 Ratings: NA Phone: (612) 813-6246 | |
Community Involvement Prog Hhs Location: 1600 Broadway Street Ne Ste 1, Minneapolis, Minnesota 55413 Ratings: NA Phone: (612) 362-4434 | |
Best Care Home Health Inc Location: 3008 University Ave Southeast, Minneapolis, Minnesota 55414 Ratings: NA Phone: (612) 378-1040 | |
Mils Home Health Care Agency Location: 2520 Broadway St Ne Ste 205, Minneapolis, Minnesota 55413 Ratings: NA Phone: (612) 379-4027 |